CAR-T cell therapy research

Optimized Multiple Amplification Protocol for the Production of Allogeneic Human Vγ9Vδ2 T Lymphocytes for Adoptive Cell Transfer Immunotherapy

This paper develops an optimized protocol to amplify allogeneic Vγ9Vδ2 T cells for adoptive cell transfer, showing they maintain antitumor activity and a pro-inflammatory profile.

Spike-in probe-enhanced single-cell RNA-seq reveals post-infusion transcriptomic remodeling of "prime-and-kill" synNotch-CAR-T cells

This paper develops a spike-in probe-enhanced scRNA-seq method to track and profile synNotch-CAR-T cells in vivo, revealing tissue-specific activation and transcriptional states.

Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic functions

This paper develops a self-amplifying RNA platform for CAR T cells that improves durability and enables multi-genic logic functions, showing superior tumor suppression in a leukemia model.

Engineering armoured in vivo CAR T cells through targeted delivery and transient mRNA gating

This paper develops an in vivo CAR T cell platform using lipid nanoparticles and T-trex strategy to enhance safety, efficacy, and tumor control.

Rational Design of Selective IL-2-based Activators for CAR T Cells Using AlphaFold3 and Physics-Informed Machine Learning

The paper computationally designs selective IL-2-based activators for CAR T cells using AlphaFold3 and physics-informed machine learning to improve therapeutic efficacy while reducing toxicity.

Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy

This paper develops a scalable, non-viral method to engineer and expand polyclonal γδ CAR-T cells, showing their functional efficacy and subset-specific responses in vivo.

VE-cadherin NOT-gated CD93 CAR T cells discriminate between AML and healthy endothelial cells

This paper develops NOT-gated CAR T cells targeting CD93 and VE-cadherin to reduce off-tumor toxicity against endothelial cells while maintaining antileukemic activity in AML.

Modulating AP-1 enables CAR-T cells to establish an intratumoral PD-1+Tcf1+ stem-like reservoir and overcomes resistance to PD-1 axis blockade

This study shows that overexpressing c-Jun in CAR-T cells enhances their ability to maintain PD-1+Tcf1+ stem-like cells in tumors and improves response to PD-L1 blockade.

L1CAM-CAR T cells with enhanced potency overcome low-density antigen expression in rhabdomyosarcoma

This study develops L1CAM-CAR T cells that effectively target rhabdomyosarcoma despite low antigen density, showing improved efficacy and safety compared to existing CARs.

MUC4-targeted CAR-T Cells Restrain Chemotherapy-resistant Colorectal Cancer

This study demonstrates that MUC4-targeted CAR-T cells effectively eliminate chemotherapy-resistant CRC cells in vitro and reduce tumor burden in vivo, showing promise for treating chemoresistant colorectal cancer.

IL-12 Secreting CAR-T Cells Reprogram the Tumor Microenvironment and Improve Efficacy Against Heterogeneous Models of Glioblastoma

This study shows that IL-12-secreting CAR-T cells improve glioblastoma treatment by enhancing T-cell persistence and reprogramming the tumor microenvironment without lymphodepletion.

Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells:Potency despite risk of translocations

This study develops next-generation CD30CAR-T cells using CRISPR/Cas9 for multiplex editing, showing high potency but risks of translocations with combined knockouts.

CARTiBASE: an interactive knowledge base for CAR sequence retrieval and similarity analysis

CARTiBASE curates and standardizes over 10,000 CAR sequences into a single resource, enabling interactive browsing, similarity search, and analysis of CAR design trends.

Enhancing CAR-T cell activity prediction via fine-tuning protein language models with generated CAR sequences

This study fine-tunes a protein language model with generated CAR sequences to predict CAR-T cell activity, showing improved performance with optimized training parameters.

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture Platform

The paper develops a microfluidic co-culture platform to generate patient-specific lymphocytes with enhanced anti-tumor activity for peritoneal malignancies.

Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy

This study identifies immunometabolic factors in CD19 CAR T cells that predict long-term response in B-ALL patients and suggests mTOR inhibition as a strategy to enhance anti-tumor activity.

A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling

This paper presents a CRISPR-based platform that removes endogenous TCRα/β chains to enhance transgenic TCR function and safety in T-cell therapies and autoimmune modeling.

Drug-controlled CAR-T cells through the regulation of cell-cell interactions

This paper develops DROP-CARs, drug-regulated CAR-T cells that control cell-cell interactions using small-molecule switches, showing in vitro and in vivo functionality.

Nanobody MET CAR T cells show efficacy in solid tumors

This study demonstrates that MET-targeting VHH-CAR-T cells effectively kill tumor cells in vitro and control tumor growth in vivo.

Mechanistic modeling predicts efficacy of CISH knockout in tumor-infiltrating lymphocytes with synergistic gene editing

The paper develops a mechanistic model to predict the efficacy of CISH knockout in TILs and identifies synergistic gene targets to enhance T cell activation.

Menin-Inhibition Sensitizes Acute Myeloid Leukemia to CLEC12A-Directed CAR Cell Therapy

This paper shows menin inhibitors increase CLEC12A expression in AML, making it more responsive to CLEC12A-targeted CAR T cells, improving treatment outcomes.

A framework for reparative CAR T engineering in the CNS

This study engineers CAR T cells to promote tissue repair in CNS injury by modulating immune responses and reducing inflammation.

CAR-T Targeting of Mutant Calreticulin Establishes a Potentially Curative Stem Cell-Directed Therapy for Myeloproliferative Neoplasms

This study demonstrates that CAR-T cells targeting mutant calreticulin can eliminate MPN-propagating HSCs in xenograft models without antigen escape.

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays

This study evaluates BLN-driven cytotoxicity in β and γδ T-cell subsets, finding β T cells show superior cytotoxicity while γδ T cells exhibit stable effector-memory states and reduced susceptibility to activation-induced cell death.

Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple Myeloma

This study uses single-cell multiomics to analyze CAR T cell dynamics in multiple myeloma, identifying regulatory mechanisms affecting persistence and dysfunction.

Intrinsically disordered insert from SH2D2A rewires CD19 CAR signaling via Tyr290

This study identifies a specific tyrosine residue in an intrinsically disordered SH2D2A sequence that rewires CD19 CAR signaling and surface expression.

Coverslip Hypoxia High-Content Screening (CH-HCS): A 2D Imaging Platform for Spatially Resolved Analysis of CAR-T Function Under Oxygen Gradients

The paper introduces CH-HCS, a 2D imaging platform that enables spatially resolved analysis of CAR-T cell function under controlled oxygen gradients, revealing hypoxia's impact on cytotoxicity and motility.

C-terminus CD28 phosphorylation (Y218) modulates IL-2 secretion and antitumor effect of CAR-T cells

This study identifies Y218 phosphorylation in CD28 as critical for IL-2 secretion and antitumor efficacy of CAR-T cells, showing that enhancing ITK recruitment improves therapeutic outcomes.

Engineering physically optimized T cells for increased sampling of complex tumor microenvironments

This study physically optimizes T cells to enhance their ability to sample and engage with pancreatic ductal adenocarcinoma tumor cells, improving therapeutic outcomes.

The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target

The paper identifies P2RX5 as a new B-cell surface marker and multi-lineage immunotherapy target, showing its expression in B-cell malignancies and T-cell leukemia, and demonstrating the efficacy of P2RX5-directed therapies.